Asensus Surgical, Inc. (AMEX: ASXC) Stock Competitors & Peer Comparison
See ASXC's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ASXC and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ASXC | $0.35 | +0.64% | 94.9M | -1.12 | -$0.31 | N/A |
| ABT | $101.95 | -1.36% | 176.4B | 19.57 | $5.21 | +2.43% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $90.96 | -0.72% | 116.5B | 16.45 | $5.53 | +3.14% |
| SYK | $275.56 | +2.06% | 105.6B | 20.58 | $13.39 | +1.27% |
| BSX | $42.98 | -0.28% | 63.9B | 13.86 | $3.10 | N/A |
| EW | $84.37 | -2.77% | 48.6B | 31.26 | $2.70 | N/A |
| DXCM | $83.03 | -1.75% | 31.3B | 32.56 | $2.55 | N/A |
| GEHC | $63.93 | -0.48% | 28.9B | 14.02 | $4.56 | +0.22% |
| PHG | $24.59 | -0.04% | 24B | 14.06 | $1.75 | +4.03% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
ASXC vs ABT Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, ABT has a market cap of 176.4B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while ABT trades at $101.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas ABT's P/E ratio is 19.57. In terms of profitability, ASXC's ROE is -1.18%, compared to ABT's ROE of +0.11%. Regarding short-term risk, ASXC is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
ASXC vs BSX-PA Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ASXC's ROE is -1.18%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ASXC is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check BSX-PA's competition here
Medtronic plc (NYSE: MDT)
ASXC vs MDT Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, MDT has a market cap of 116.5B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while MDT trades at $90.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas MDT's P/E ratio is 16.45. In terms of profitability, ASXC's ROE is -1.18%, compared to MDT's ROE of +0.11%. Regarding short-term risk, ASXC is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
ASXC vs SYK Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, SYK has a market cap of 105.6B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while SYK trades at $275.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas SYK's P/E ratio is 20.58. In terms of profitability, ASXC's ROE is -1.18%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ASXC is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
ASXC vs BSX Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, BSX has a market cap of 63.9B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while BSX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas BSX's P/E ratio is 13.86. In terms of profitability, ASXC's ROE is -1.18%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ASXC is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
ASXC vs EW Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, EW has a market cap of 48.6B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while EW trades at $84.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas EW's P/E ratio is 31.26. In terms of profitability, ASXC's ROE is -1.18%, compared to EW's ROE of +0.10%. Regarding short-term risk, ASXC is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
ASXC vs DXCM Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, DXCM has a market cap of 31.3B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while DXCM trades at $83.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas DXCM's P/E ratio is 32.56. In terms of profitability, ASXC's ROE is -1.18%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, ASXC is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
ASXC vs GEHC Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, GEHC has a market cap of 28.9B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while GEHC trades at $63.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas GEHC's P/E ratio is 14.02. In terms of profitability, ASXC's ROE is -1.18%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ASXC is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
ASXC vs PHG Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, PHG has a market cap of 24B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while PHG trades at $24.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas PHG's P/E ratio is 14.06. In terms of profitability, ASXC's ROE is -1.18%, compared to PHG's ROE of +0.10%. Regarding short-term risk, ASXC is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
ASXC vs ZBH Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, ZBH has a market cap of 18.1B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while ZBH trades at $93.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas ZBH's P/E ratio is 11.02. In terms of profitability, ASXC's ROE is -1.18%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ASXC is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
ASXC vs ABMD Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ASXC's ROE is -1.18%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ASXC is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check ABMD's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
ASXC vs SWAV Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ASXC's ROE is -1.18%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ASXC is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check SWAV's competition here
Penumbra, Inc. (NYSE: PEN)
ASXC vs PEN Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while PEN trades at $317.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas PEN's P/E ratio is 82.97. In terms of profitability, ASXC's ROE is -1.18%, compared to PEN's ROE of +0.11%. Regarding short-term risk, ASXC is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
ASXC vs SNN Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, SNN has a market cap of 11.5B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while SNN trades at $27.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas SNN's P/E ratio is 12.93. In terms of profitability, ASXC's ROE is -1.18%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ASXC is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
ASXC vs ALGN Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, ALGN has a market cap of 10.8B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while ALGN trades at $150.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas ALGN's P/E ratio is 13.75. In terms of profitability, ASXC's ROE is -1.18%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, ASXC is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
ASXC vs GMED Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, GMED has a market cap of 10B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while GMED trades at $74.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas GMED's P/E ratio is 16.71. In terms of profitability, ASXC's ROE is -1.18%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ASXC is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check GMED's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
ASXC vs BIO-B Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, BIO-B has a market cap of 10B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while BIO-B trades at $365.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas BIO-B's P/E ratio is -64.28. In terms of profitability, ASXC's ROE is -1.18%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, ASXC is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
ASXC vs BIO Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, BIO has a market cap of 9.9B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while BIO trades at $369.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas BIO's P/E ratio is 39.76. In terms of profitability, ASXC's ROE is -1.18%, compared to BIO's ROE of +0.03%. Regarding short-term risk, ASXC is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check BIO's competition here
Glaukos Corporation (NYSE: GKOS)
ASXC vs GKOS Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, GKOS has a market cap of 9.9B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while GKOS trades at $167.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas GKOS's P/E ratio is -194.59. In terms of profitability, ASXC's ROE is -1.18%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, ASXC is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check GKOS's competition here
Masimo Corporation (NASDAQ: MASI)
ASXC vs MASI Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas MASI's P/E ratio is 44.43. In terms of profitability, ASXC's ROE is -1.18%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ASXC is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check MASI's competition here
Insulet Corp. (NASDAQ: PODD)
ASXC vs PODD Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, PODD has a market cap of 9.1B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while PODD trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas PODD's P/E ratio is 22.48. In terms of profitability, ASXC's ROE is -1.18%, compared to PODD's ROE of +0.27%. Regarding short-term risk, ASXC is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check PODD's competition here
Bruker Corporation (NASDAQ: BRKR)
ASXC vs BRKR Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, BRKR has a market cap of 8.1B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while BRKR trades at $53.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas BRKR's P/E ratio is 26.85. In terms of profitability, ASXC's ROE is -1.18%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, ASXC is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
ASXC vs BRKRP Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, BRKRP has a market cap of 8B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while BRKRP trades at $399.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas BRKRP's P/E ratio is 216.13. In terms of profitability, ASXC's ROE is -1.18%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, ASXC is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check BRKRP's competition here
Inari Medical, Inc. (NASDAQ: NARI)
ASXC vs NARI Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas NARI's P/E ratio is -59.24. In terms of profitability, ASXC's ROE is -1.18%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ASXC is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check NARI's competition here
Haemonetics Corporation (NYSE: HAE)
ASXC vs HAE Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, HAE has a market cap of 4.7B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while HAE trades at $102.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas HAE's P/E ratio is 20.50. In terms of profitability, ASXC's ROE is -1.18%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ASXC is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
ASXC vs LIVN Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while LIVN trades at $78.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas LIVN's P/E ratio is 18.57. In terms of profitability, ASXC's ROE is -1.18%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ASXC is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
ASXC vs ITGR Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while ITGR trades at $126.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas ITGR's P/E ratio is 19.84. In terms of profitability, ASXC's ROE is -1.18%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, ASXC is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
ASXC vs IRTC Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while IRTC trades at $111.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas IRTC's P/E ratio is -259.14. In terms of profitability, ASXC's ROE is -1.18%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, ASXC is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
ASXC vs AXNX Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ASXC's ROE is -1.18%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ASXC is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
ASXC vs TMDX Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, TMDX has a market cap of 2.8B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while TMDX trades at $82.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas TMDX's P/E ratio is 41.72. In terms of profitability, ASXC's ROE is -1.18%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, ASXC is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check TMDX's competition here
Neogen Corporation (NASDAQ: NEOG)
ASXC vs NEOG Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while NEOG trades at $11.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas NEOG's P/E ratio is 42.07. In terms of profitability, ASXC's ROE is -1.18%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, ASXC is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check NEOG's competition here
AxoGen, Inc. (NASDAQ: AXGN)
ASXC vs AXGN Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while AXGN trades at $42.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas AXGN's P/E ratio is 110.95. In terms of profitability, ASXC's ROE is -1.18%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, ASXC is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
ASXC vs UFPT Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while UFPT trades at $277.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas UFPT's P/E ratio is 28.39. In terms of profitability, ASXC's ROE is -1.18%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ASXC is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check UFPT's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
ASXC vs INSP Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, INSP has a market cap of 2.1B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while INSP trades at $73.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas INSP's P/E ratio is 32.18. In terms of profitability, ASXC's ROE is -1.18%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ASXC is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check INSP's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
ASXC vs ESTA Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while ESTA trades at $70.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas ESTA's P/E ratio is -56.30. In terms of profitability, ASXC's ROE is -1.18%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ASXC is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
ASXC vs NUVA Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ASXC's ROE is -1.18%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ASXC is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check NUVA's competition here
Butterfly Network, Inc. (NYSE: BFLY)
ASXC vs BFLY Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, BFLY has a market cap of 1.9B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while BFLY trades at $7.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas BFLY's P/E ratio is -30.48. In terms of profitability, ASXC's ROE is -1.18%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, ASXC is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check BFLY's competition here
Novocure Ltd (NASDAQ: NVCR)
ASXC vs NVCR Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while NVCR trades at $15.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas NVCR's P/E ratio is -11.93. In terms of profitability, ASXC's ROE is -1.18%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, ASXC is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
ASXC vs ATEC Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while ATEC trades at $10.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas ATEC's P/E ratio is -176.33. In terms of profitability, ASXC's ROE is -1.18%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, ASXC is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
ASXC vs CNMD Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while CNMD trades at $46.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas CNMD's P/E ratio is 10.19. In terms of profitability, ASXC's ROE is -1.18%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, ASXC is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
ASXC vs HSKA Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ASXC's ROE is -1.18%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ASXC is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check HSKA's competition here
Artivion, Inc. (NYSE: AORT)
ASXC vs AORT Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while AORT trades at $25.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas AORT's P/E ratio is 41.80. In terms of profitability, ASXC's ROE is -1.18%, compared to AORT's ROE of -0.01%. Regarding short-term risk, ASXC is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check AORT's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
ASXC vs IART Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while IART trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas IART's P/E ratio is 6.57. In terms of profitability, ASXC's ROE is -1.18%, compared to IART's ROE of -0.01%. Regarding short-term risk, ASXC is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check IART's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
ASXC vs TNDM Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while TNDM trades at $17.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas TNDM's P/E ratio is -18.40. In terms of profitability, ASXC's ROE is -1.18%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, ASXC is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check TNDM's competition here
Avanos Medical, Inc. (NYSE: AVNS)
ASXC vs AVNS Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ASXC's ROE is -1.18%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ASXC is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check AVNS's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
ASXC vs PRCT Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while PRCT trades at $20.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas PRCT's P/E ratio is -10.51. In terms of profitability, ASXC's ROE is -1.18%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, ASXC is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check PRCT's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
ASXC vs SILK Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas SILK's P/E ratio is -18.96. In terms of profitability, ASXC's ROE is -1.18%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ASXC is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check SILK's competition here
Enovis Corporation (NYSE: ENOV)
ASXC vs ENOV Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while ENOV trades at $19.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas ENOV's P/E ratio is 5.52. In terms of profitability, ASXC's ROE is -1.18%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, ASXC is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check ENOV's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
ASXC vs LMRI Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while LMRI trades at $11.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas LMRI's P/E ratio is -22.36. In terms of profitability, ASXC's ROE is -1.18%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ASXC is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check LMRI's competition here
Paragon 28, Inc. (NYSE: FNA)
ASXC vs FNA Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas FNA's P/E ratio is -19.83. In terms of profitability, ASXC's ROE is -1.18%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ASXC is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check FNA's competition here
IRadimed Corporation (NASDAQ: IRMD)
ASXC vs IRMD Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while IRMD trades at $82.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas IRMD's P/E ratio is 41.32. In terms of profitability, ASXC's ROE is -1.18%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ASXC is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check IRMD's competition here
CeriBell, Inc. (NASDAQ: CBLL)
ASXC vs CBLL Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, CBLL has a market cap of 896.6M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while CBLL trades at $23.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas CBLL's P/E ratio is -13.43. In terms of profitability, ASXC's ROE is -1.18%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, ASXC is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check CBLL's competition here
Bioventus Inc. (NASDAQ: BVS)
ASXC vs BVS Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, BVS has a market cap of 879.4M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while BVS trades at $12.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas BVS's P/E ratio is 17.08. In terms of profitability, ASXC's ROE is -1.18%, compared to BVS's ROE of +0.28%. Regarding short-term risk, ASXC is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check BVS's competition here
InMode Ltd. (NASDAQ: INMD)
ASXC vs INMD Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, INMD has a market cap of 856.5M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while INMD trades at $14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas INMD's P/E ratio is 10.35. In terms of profitability, ASXC's ROE is -1.18%, compared to INMD's ROE of +0.12%. Regarding short-term risk, ASXC is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
ASXC vs CSII Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas CSII's P/E ratio is -20.83. In terms of profitability, ASXC's ROE is -1.18%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ASXC is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check CSII's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
ASXC vs AHCO Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, AHCO has a market cap of 824.5M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while AHCO trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas AHCO's P/E ratio is 12.37. In terms of profitability, ASXC's ROE is -1.18%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, ASXC is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check AHCO's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
ASXC vs SIBN Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, SIBN has a market cap of 815.1M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while SIBN trades at $18.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas SIBN's P/E ratio is -54.06. In terms of profitability, ASXC's ROE is -1.18%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ASXC is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check SIBN's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
ASXC vs AVR Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, AVR has a market cap of 811.9M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while AVR trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas AVR's P/E ratio is -4.30. In terms of profitability, ASXC's ROE is -1.18%, compared to AVR's ROE of -0.78%. Regarding short-term risk, ASXC is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check AVR's competition here
Varex Imaging Corporation (NASDAQ: VREX)
ASXC vs VREX Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, VREX has a market cap of 777.2M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while VREX trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas VREX's P/E ratio is 19.43. In terms of profitability, ASXC's ROE is -1.18%, compared to VREX's ROE of +0.05%. Regarding short-term risk, ASXC is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check VREX's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
ASXC vs BBNX Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, BBNX has a market cap of 745.5M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while BBNX trades at $16.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas BBNX's P/E ratio is -10.04. In terms of profitability, ASXC's ROE is -1.18%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, ASXC is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check BBNX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
ASXC vs SSII Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, SSII has a market cap of 662.4M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while SSII trades at $3.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas SSII's P/E ratio is -64.56. In terms of profitability, ASXC's ROE is -1.18%, compared to SSII's ROE of -0.27%. Regarding short-term risk, ASXC is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
ASXC vs SRDX Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ASXC's ROE is -1.18%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ASXC is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
ASXC vs CTKB Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, CTKB has a market cap of 595.3M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while CTKB trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas CTKB's P/E ratio is -24.42. In terms of profitability, ASXC's ROE is -1.18%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, ASXC is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check CTKB's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
ASXC vs APEN Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas APEN's P/E ratio is -9.43. In terms of profitability, ASXC's ROE is -1.18%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ASXC is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
ASXC vs KIDS Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, KIDS has a market cap of 566.6M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while KIDS trades at $22.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas KIDS's P/E ratio is -18.69. In terms of profitability, ASXC's ROE is -1.18%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, ASXC is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check KIDS's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
ASXC vs DCTH Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, DCTH has a market cap of 549.2M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while DCTH trades at $15.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas DCTH's P/E ratio is 1591.00. In terms of profitability, ASXC's ROE is -1.18%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, ASXC is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
ASXC vs ZIMV Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ASXC's ROE is -1.18%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, ASXC is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
ASXC vs TCMD Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, TCMD has a market cap of 505.3M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while TCMD trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas TCMD's P/E ratio is 20.74. In terms of profitability, ASXC's ROE is -1.18%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, ASXC is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check TCMD's competition here
Cerus Corporation (NASDAQ: CERS)
ASXC vs CERS Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, CERS has a market cap of 501.8M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while CERS trades at $2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas CERS's P/E ratio is -49.70. In terms of profitability, ASXC's ROE is -1.18%, compared to CERS's ROE of -0.10%. Regarding short-term risk, ASXC is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
ASXC vs NPCE Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, NPCE has a market cap of 478.7M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while NPCE trades at $14.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas NPCE's P/E ratio is -24.63. In terms of profitability, ASXC's ROE is -1.18%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, ASXC is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check NPCE's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
ASXC vs SGHT Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, SGHT has a market cap of 442.9M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while SGHT trades at $8.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas SGHT's P/E ratio is -14.54. In terms of profitability, ASXC's ROE is -1.18%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, ASXC is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check SGHT's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ASXC vs CLPT Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, CLPT has a market cap of 411.5M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while CLPT trades at $13.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas CLPT's P/E ratio is -11.63. In terms of profitability, ASXC's ROE is -1.18%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, ASXC is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check CLPT's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
ASXC vs PACB Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, PACB has a market cap of 403.8M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while PACB trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas PACB's P/E ratio is -3.17. In terms of profitability, ASXC's ROE is -1.18%, compared to PACB's ROE of -49.62%. Regarding short-term risk, ASXC is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check PACB's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
ASXC vs SENS Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, SENS has a market cap of 364M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while SENS trades at $8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas SENS's P/E ratio is -3.91. In terms of profitability, ASXC's ROE is -1.18%, compared to SENS's ROE of -1.66%. Regarding short-term risk, ASXC is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
ASXC vs OFIX Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, OFIX has a market cap of 361M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while OFIX trades at $8.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas OFIX's P/E ratio is -5.82. In terms of profitability, ASXC's ROE is -1.18%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, ASXC is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
ASXC vs CV Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, CV has a market cap of 329.8M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while CV trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas CV's P/E ratio is -10.48. In terms of profitability, ASXC's ROE is -1.18%, compared to CV's ROE of -1.78%. Regarding short-term risk, ASXC is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check CV's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
ASXC vs CATX Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, CATX has a market cap of 321M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while CATX trades at $2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas CATX's P/E ratio is -2.12. In terms of profitability, ASXC's ROE is -1.18%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ASXC is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check CATX's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
ASXC vs SMLR Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ASXC's ROE is -1.18%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, ASXC is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
ASXC vs TMCI Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, TMCI has a market cap of 292.6M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while TMCI trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas TMCI's P/E ratio is -4.80. In terms of profitability, ASXC's ROE is -1.18%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, ASXC is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check TMCI's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
ASXC vs TLSI Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, TLSI has a market cap of 287.2M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while TLSI trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas TLSI's P/E ratio is -2.78. In terms of profitability, ASXC's ROE is -1.18%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, ASXC is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check TLSI's competition here
RxSight, Inc. (NASDAQ: RXST)
ASXC vs RXST Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, RXST has a market cap of 249.2M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while RXST trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas RXST's P/E ratio is -5.33. In terms of profitability, ASXC's ROE is -1.18%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ASXC is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check RXST's competition here
Avita Medical Inc. (NASDAQ: RCEL)
ASXC vs RCEL Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, RCEL has a market cap of 245.4M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while RCEL trades at $9.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas RCEL's P/E ratio is -6.86. In terms of profitability, ASXC's ROE is -1.18%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, ASXC is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check RCEL's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
ASXC vs INFU Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, INFU has a market cap of 245.2M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while INFU trades at $12.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas INFU's P/E ratio is 29.63. In terms of profitability, ASXC's ROE is -1.18%, compared to INFU's ROE of +0.15%. Regarding short-term risk, ASXC is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
ASXC vs MGRM Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ASXC's ROE is -1.18%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, ASXC is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
ASXC vs ELMD Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, ELMD has a market cap of 225.5M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while ELMD trades at $27.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas ELMD's P/E ratio is 20.79. In terms of profitability, ASXC's ROE is -1.18%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, ASXC is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
ASXC vs NVRO Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ASXC's ROE is -1.18%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ASXC is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check NVRO's competition here
Profound Medical Corp. (NASDAQ: PROF)
ASXC vs PROF Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, PROF has a market cap of 216.9M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while PROF trades at $5.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas PROF's P/E ratio is -6.09. In terms of profitability, ASXC's ROE is -1.18%, compared to PROF's ROE of -0.56%. Regarding short-term risk, ASXC is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check PROF's competition here
Neuronetics, Inc. (NASDAQ: STIM)
ASXC vs STIM Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, STIM has a market cap of 210.9M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while STIM trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas STIM's P/E ratio is -6.89. In terms of profitability, ASXC's ROE is -1.18%, compared to STIM's ROE of -1.51%. Regarding short-term risk, ASXC is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
ASXC vs BSGM Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ASXC's ROE is -1.18%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, ASXC is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
ASXC vs MDGS Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ASXC's ROE is -1.18%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ASXC is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
ASXC vs QIPT Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ASXC's ROE is -1.18%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ASXC is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
ASXC vs FOCL Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, FOCL has a market cap of 153.7M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while FOCL trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas FOCL's P/E ratio is -3.96. In terms of profitability, ASXC's ROE is -1.18%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, ASXC is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check FOCL's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
ASXC vs LUCD Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, LUCD has a market cap of 149.4M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while LUCD trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas LUCD's P/E ratio is -2.12. In terms of profitability, ASXC's ROE is -1.18%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, ASXC is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check LUCD's competition here
Quantum-Si incorporated (NASDAQ: QSI)
ASXC vs QSI Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, QSI has a market cap of 148.7M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while QSI trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas QSI's P/E ratio is -1.63. In terms of profitability, ASXC's ROE is -1.18%, compared to QSI's ROE of -0.47%. Regarding short-term risk, ASXC is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check QSI's competition here
Inogen, Inc. (NASDAQ: INGN)
ASXC vs INGN Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, INGN has a market cap of 143.8M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while INGN trades at $5.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas INGN's P/E ratio is -5.84. In terms of profitability, ASXC's ROE is -1.18%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ASXC is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
ASXC vs QTRX Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, QTRX has a market cap of 120.6M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while QTRX trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas QTRX's P/E ratio is -1.01. In terms of profitability, ASXC's ROE is -1.18%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, ASXC is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
ASXC vs ICAD Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ASXC's ROE is -1.18%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ASXC is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ASXC.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
ASXC vs HJLI Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas HJLI's P/E ratio is N/A. In terms of profitability, ASXC's ROE is -1.18%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, ASXC is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check HJLI's competition here
LENSAR Inc (NASDAQ: LNSR)
ASXC vs LNSR Comparison September 2026
Asensus Surgical, Inc. (AMEX: ASXC) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASXC stands at 94.9M. In comparison, LNSR has a market cap of 93.3M. Regarding current trading prices, ASXC is priced at $0.35 on the AMEX, while LNSR trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASXC currently has a P/E ratio of -1.12, whereas LNSR's P/E ratio is 6.18. In terms of profitability, ASXC's ROE is -1.18%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, ASXC is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for ASXC.Check LNSR's competition here